⚠️ Serious warning: Nothing on this website is approved by any physician. Doz is only a tool to help physicians and to search drugs easily. Taking medicines without medical supervision can be fatal.

Dexmethylphenidate

دکس‌متیل‌فنیدیت

⚠ Unverified

🧠 Nervous SystemCNS stimulant

🤰 Pregnancy:Use with caution 🤱 Breastfeeding:Use with caution 👶 Children:Use with caution 👴 Older adults:Use with caution 🇮🇷 Not found in Iran list ⛔ 1 contraindications 🇺🇸 FDA approved (NDA) NDA021278 ATC N06BA11

Market / country: 🇺🇸 USA

Focalin (US)

🧮 Dose calculator

Disease / regimen

Attention-deficit/hyperactivity disorder · Regimen source: FDA Focalin · 2.2

• Increase by 2.5–5 mg weekly. If already on methylphenidate: half the daily methylphenidate dose. Screen for cardiac disease and tics first. Stop if no improvement within a month. FDA Focalin · 2.2 FDA Focalin · 2.1 FDA Focalin · 2.4

Formulation

Age *

Weight (kg) (optional)

Enter age (weight is optional for this regimen).

🛡️ Safety & information

Contraindications

⛔ Hypersensitivity to methylphenidate; MAOIs concomitantly or within 14 days (hypertensive crisis). FDA Focalin · 4

Warnings

• Boxed warning: high potential for abuse, misuse and addiction, overdose and death. FDA Focalin · Boxed Warning
• Risk in serious cardiac disease; raised BP and HR; psychiatric reactions; priapism; Raynaud; growth suppression in children; glaucoma; tics. FDA Focalin · 5

Formulations

2.5 mg tablet — tablet 🇺🇸 USA FDA Focalin · 3
5 mg tablet — tablet 🇺🇸 USA FDA Focalin · 3
10 mg tablet — tablet 🇺🇸 USA FDA Focalin · 3

👥 Special populations

🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Focalin · 8.1
“Risk Summary Dexmethylphenidate is the d-threo enantiomer of racemic methylphenidate.”
🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Focalin · 8.2
“Risk Summary Dexmethylphenidate is the d-threo enantiomer of racemic methylphenidate.”
👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Focalin · 8.4
“The safety and effectiveness of Focalin have been established in pediatric patients aged 6 to 17 years in two adequate and well-controlled clinical trials [see Clinical Studies ( 14 )] .”
👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Focalin · 8.5
“Focalin has not been studied in the geriatric population.”
⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.

🔗 Reference links

FDA (approval record)NDA021278
DailyMed (FDA label)FDA Focalin
MedlinePlus (NIH)Dexmethylphenidate
WHO ATC/DDDN06BA11
Darooyab (Iran)Dexmethylphenidate

🇮🇷 Not found in Iran list Darooyab · G-3375/Dexmethylphenidate

Darooyab lists no registered dosage form or brand for this drug. This does not prove it is unavailable.

📚 Reference status for this drug

Shows which sources have references recorded for this drug and which do not.

FDA label (DailyMed)✅ Present
FDA Focalin · 3 FDA Focalin · 2.2 FDA Focalin · 2.1 FDA Focalin · 2.4 FDA Focalin · 4 FDA Focalin · Boxed Warning FDA Focalin · 5 FDA Focalin · 8.1 FDA Focalin · 8.2 FDA Focalin · 8.4 FDA Focalin · 8.5 FDA Focalin · SPL approval / marketing category
UK SmPC (eMC / MHRA)❌ Not present
Published guideline❌ Not present
Licensed reference (medical school)❌ Not present
Iranian leaflet (IFDA)❌ Not present
Pharmacy website (secondary, unreliable)✅ Present
Darooyab · G-3375/Dexmethylphenidate
Clinical review⚠ Unverified